SCHEMBL4369490

SCHEMBL4369490

Cc1ccc(CN[C@@H](CCC(N)=O)C(=O)OC(=O)c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
SLC1A5 Q15758 1/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
MAPK14 Q16539 1/20 0.39
TLR2 O60603 2/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HDAC1 Q13547 1/20 0.39
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651085 0.89 RAB9A (0.43) KDM4EMMP2MMP9MAPTRAB9A
SCHEMBL5653527 0.88 SMN1; SMN2 (0.47) KDM4ESMN1; SMN2MMP2MMP9SLC1A5
SCHEMBL4359340 0.87 KDM4E (0.42) KDM4ESMN1; SMN2MMP2MMP9SLC1A5
SCHEMBL5654173 0.85 KDM4E (0.44) KDM4EMEN1KMT2ASMN1; SMN2MMP2
SCHEMBL4365892 0.85 KDM4E (0.42) KDM4EMEN1KMT2ASMN1; SMN2MMP2
SCHEMBL2247824 0.84 POLB (0.37) KDM4EMAPTALDH1A1POLBRAB9A
SCHEMBL2251695 0.83 SMN1; SMN2 (0.45) KDM4EMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL5655905 0.82 KDM4E (0.42) KDM4EMEN1KMT2ASMN1; SMN2MMP2
SCHEMBL2244761 0.81 F2 (0.38) KDM4EMAPTALDH1A1POLB
SCHEMBL5651555 0.81 KDM4E (0.51) KDM4EKMT2ASMN1; SMN2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 KDM4E 1232/4885MEN1 2734/4885KMT2A 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.